Nyxoah Company

Nyxoah is a pioneering medical device company, engaged in developing a novel diagnostic and therapeutic solution to combat Obstructive Sleep Apnea (OSA). The company is driven by the vision that OSA sufferers should not be encumbered by clumsy devices or complex and expensive surgical procedures. Technology should be harnessed in a way that promises the best quality of life and the least possible discomfort. Nyxoah was founded in 2009 by Robert Taub and Dr Adi Mashiach to extend the capabilities of alternative OSA treatments focused on Neurostimulation. It is currently engaged in clinical tests of a tiny, battery-less implantable neurostimulator that can electrically control the nerves of the tongue and so prevent airway blockage. An added innovation is that Nyxoah's technology can monitor the tongue and stimulate the muscles only when it blocks the airway. The fundamental difference to competitive neurostimulation devices is the triple advantage of low cost, ease of implantation and significantly lower risk of migration away from the defined implantation site. In developing the next generation of neurostimulation devices, Nyxoah is working closely with leading experts on breathing disorders during sleep. The company is set to make a real difference to those whose lives are disrupted or threatened by OSA.
Technology: NeuroTech
Industry: Biotechnology, Health Care, Science and Engineering
Headquarters: Mont-saint-guibert, Brabant Wallon, Belgium
Founded Date: 2009-01-01
Employees Number: 11-50
Investors Number: 5
Total Funding: €66M
Estimated Revenue: $1M to $10M
Last Funding Type: Corporate Round

Visit Website
Register and Claim Ownership